Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy

References

• TsangRYAl-FayeaTAuHJCisplatin overdose: toxicities and managementDrug Safety200932121109112219916578
   PubMed Web of Science ®Google Scholar
• HuangHZhuLReidBRDrobnyGPHopkinsPBSolution structure of a cisplatin-induced DNA interstrand cross-linkScience19952705243184218458525382
   PubMed Web of Science ®Google Scholar
• QuasthoffSHartungHPChemotherapy-induced peripheral neuropathyJ Neurol2002249191711954874
   PubMed Web of Science ®Google Scholar
• StarobovaHVetterIPathophysiology of chemotherapy-induced peripheral neuropathyFront Mol Neurosci20171017428620280
   PubMed Web of Science ®Google Scholar
• AmptoulachSTsavarisNNeurotoxicity caused by the treatment with platinum analoguesChemother Res Pract2011201184301922312559
   PubMedGoogle Scholar
• GreggRWMolepoJMMonpetitVJCisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicityJ Clin Oncol19921057958031569451
   PubMed Web of Science ®Google Scholar
• ArgyriouAABrunaJMarmiroliPCavalettiGChemotherapy-induced peripheral neurotoxicity (CIPN): an updateCrit Rev Oncol Hematol2012821517721908200
   PubMed Web of Science ®Google Scholar
• SuttonGBrunettoVLKilgoreLA phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group StudyGynecol Oncol200079214715311063636
   PubMed Web of Science ®Google Scholar
• GatzemeierUvon PawelJGottfriedMPhase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancerJ Clin Oncol200018193390339911013280
   PubMed Web of Science ®Google Scholar
• BaronRBinderAWasnerGNeuropathic pain: diagnosis, pathophysiological mechanisms, and treatmentLancet Neurol20109880781920650402
   PubMed Web of Science ®Google Scholar
• CostiganMScholzJWoolfCJNeuropathic pain: a maladaptive response of the nervous system to damageAnnu Rev Neurosci20093213219400724
   PubMed Web of Science ®Google Scholar
• ThompsonSWDavisLEKornfeldMHilgersRDStandeferJCCisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studiesCancer1984547126912756088023
   PubMed Web of Science ®Google Scholar
• Krarup-HansenARietzBKrarupCHeydornKRorthMSchmalbruchHHistology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy studyNeuropathol Appl Neurobiol1999251294010194773
   PubMed Web of Science ®Google Scholar
• DzagnidzeAKatsaravaZMakhalovaJRepair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathyJ Neurosci200727359451945717728458
   PubMed Web of Science ®Google Scholar
• AllenDTKiernanJAPermeation of proteins from the blood into peripheral nerves and gangliaNeuroscience19945937557648008217
   PubMed Web of Science ®Google Scholar
• KanatOErtasHCanerBPlatinum-induced neurotoxicity: a review of possible mechanismsWorld J Clin Oncol20178432933528848699
   PubMed Web of Science ®Google Scholar
• NamikawaKAsakuraMMinamiTOkazakiYKadotaEHashimotoSToxicity of cisplatin to the central nervous system of male rabbitsBiol Trace Elem Res200074322323511055809
   PubMed Web of Science ®Google Scholar
• CeceRPetruccioliMGPizziniGCavalettiGTrediciGUltrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathyJ Submicrosc Cytol Pathol19952744174257585442
   PubMed Web of Science ®Google Scholar
• LeesJGMakkerPGTonkinRSImmune-mediated processes implicated in chemotherapy-induced peripheral neuropathyEur J Cancer201773222928104535
   PubMed Web of Science ®Google Scholar
• CavalettiGCeresaCNicoliniGMarmiroliPNeuronal drug transporters in platinum drugs-induced peripheral neurotoxicityAnticancer Res201434148348624403505
   PubMed Web of Science ®Google Scholar
• McDonaldESRandonKRKnightAWindebankAJCisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicityNeurobiol Dis200518230531315686959
   PubMed Web of Science ®Google Scholar
• GillJSWindebankAJCisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycleJ Clin Invest199810112284228509637718
   PubMed Web of Science ®Google Scholar
• CantaAPozziECarozziVAMitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN)Toxics20153219822329056658
   PubMedGoogle Scholar
• PodratzJLKnightAMTaLECisplatin induced mitochondrial DNA damage in dorsal root ganglion neuronsNeurobiol Dis201141366166821145397
   PubMed Web of Science ®Google Scholar
• ScuteriAGalimbertiAMaggioniDRole of MAPKs in platinum-induced neuronal apoptosisNeurotoxicology200930231231919428505
   PubMed Web of Science ®Google Scholar
• CarozziVACantaAChiorazziAChemotherapy-induced peripheral neuropathy: what do we know about mechanisms?Neurosci Lett20155969010725459280
   PubMed Web of Science ®Google Scholar
• TaLEBieberAJCarltonSMLoprinziCLLowPAWindebankAJTransient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in miceMol Pain201061520205720
   PubMed Web of Science ®Google Scholar
• AlbersJWChaudhryVCavalettiGDonehowerRCInterventions for preventing neuropathy caused by cisplatin and related compoundsCochrane Database Syst Rev2014313Cd005228
   Google Scholar
• FerreiraRSDos SantosNAGMartinsNMFernandesLSDos SantosACCaffeic acid phenethyl ester (CAPE) protects PC12 cells from cisplatin-induced neurotoxicity by activating the NGF-signaling pathwayNeurotox Res Epub20171219
   Web of Science ®Google Scholar
• MajMAMaJKrukowskiKNKavelaarsAHeijnenCJInhibition of mitochondrial p53 accumulation by PFT-mu prevents cisplatin-induced peripheral neuropathyFront Mol Neurosci20171010828458631
   PubMed Web of Science ®Google Scholar
• KelleyMRWikelJHGuoCIdentification and characterization of new chemical entities targeting apurinic/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathyJ Pharmacol Exp Ther2016359230030927608656
   PubMed Web of Science ®Google Scholar
• ScuteriARavasiMMonfriniMHuman mesenchymal stem cells protect dorsal root ganglia from the neurotoxic effect of cisplatinAnticancer Res201535105383538926408700
   PubMed Web of Science ®Google Scholar
• MechoulamRHanusLOPertweeRHowlettACEarly phytocannabinoid chemistry to endocannabinoids and beyondNat Rev Neurosci2014151175776425315390
   PubMed Web of Science ®Google Scholar
• PacherPBatkaiSKunosGThe endocannabinoid system as an emerging target of pharmacotherapyPharmacol Rev200658338946216968947
   PubMed Web of Science ®Google Scholar
• GrotenhermenFMuller-VahlKThe therapeutic potential of cannabis and cannabinoidsDtsch Arztebl Int201210929–3049550123008748
   PubMed Web of Science ®Google Scholar
• AtakanZCannabis, a complex plant: different compounds and different effects on individualsTher Adv Psychopharmacol20122624125423983983
   PubMedGoogle Scholar
• United NationsSingle Convention on Narcotic Drugs 1961New York, NYUnited Nations1962
   Google Scholar
• LuongoLStarowiczKMaioneSDi MarzoVAllodynia lowering induced by cannabinoids and endocannabinoids (ALICE)Pharmacol Res201711927227728237514
   PubMed Web of Science ®Google Scholar
• GuindonJHohmannAGThe endocannabinoid system and painCNS Neurol Disord Drug Targets20098640342119839937
   PubMed Web of Science ®Google Scholar
• PiomelliDSassoOPeripheral gating of pain signals by endogenous analgesic lipidsNat Neurosci201417216417424473264
   PubMed Web of Science ®Google Scholar
• WhitesideGTLeeGPValenzanoKJThe role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonistsCurr Med Chem200714891793617430144
   PubMed Web of Science ®Google Scholar
• HillKPPalastroMDJohnsonBDitreJWCannabis and pain: a clinical reviewCannabis Cannabinoid Res2017219610428861509
   PubMedGoogle Scholar
• MaldonadoRBanosJECabaneroDThe endocannabinoid system and neuropathic painPain2016157suppl 1S23S3226785153
   PubMed Web of Science ®Google Scholar
• RahnEJHohmannAGCannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedsideNeurotherapeutics20096471373719789075
   PubMed Web of Science ®Google Scholar
• CostaBTrovatoAEColleoniMGiagnoniGZariniECrociTEffect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nervePain20051161–2526115936882
   PubMed Web of Science ®Google Scholar
• RiceASFarquhar-SmithWPNagyIEndocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathyProstaglandins Leukot Essent Fatty Acids2002662–324325612052040
   PubMed Web of Science ®Google Scholar
• MitrirattanakulSRamakulNGuerreroAVSite-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic painPain20061261–310211416844297
   PubMed Web of Science ®Google Scholar
• ZhangJHoffertCVuHKGroblewskiTAhmadSO’DonnellDInduction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain modelsEur J Neurosci200317122750275412823482
   PubMed Web of Science ®Google Scholar
• JhaveriMDRichardsonDChapmanVEndocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory painBr J Pharmacol2007152562463217704819
   PubMed Web of Science ®Google Scholar
• MengHJohnstonBEnglesakisMMoulinDEBhatiaASelective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysisAnesth Analg201712551638165228537982
   PubMed Web of Science ®Google Scholar
• LiangYCHuangCCHsuKSThe synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic painNeuropharmacology200753116917717572451
   PubMed Web of Science ®Google Scholar
• GuindonJDesrochesJDaniMBeaulieuPPre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic painEur J Pharmacol20075681–317317617555742
   PubMed Web of Science ®Google Scholar
• BridgesDAhmadKRiceASCThe synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic painBr J Pharmacol2001133458659411399676
   PubMed Web of Science ®Google Scholar
• CostaBColleoniMContiSRepeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic painBr J Pharmacol200414114814662732
   PubMed Web of Science ®Google Scholar
• LeverIJPhebyTMRiceASContinuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivityBr J Pharmacol2007151229230217375083
   PubMed Web of Science ®Google Scholar
• LiALCareyLMMackieKHohmannAGCannabinoid CB2 agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in miceJ Pharmacol Exp Ther2017362229630528592614
   PubMed Web of Science ®Google Scholar
• CaseySLAtwalNVaughanCWCannabis constituent synergy in a mouse neuropathic pain modelPain2017158122452246028885457
   PubMed Web of Science ®Google Scholar
• CostaBTrovatoAEComelliFGiagnoniGColleoniMThe non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic painEur J Pharmacol20075561–3758317157290
   PubMed Web of Science ®Google Scholar
• KazantzisNPCaseySLSeowPWMitchellVAVaughanCWOpioid and cannabinoid synergy in a mouse neuropathic pain modelBr J Pharmacol2016173162521253127278681
   PubMed Web of Science ®Google Scholar
• GunduzOTopuzRDKaradagCHUlugolAAnalysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic miceEur J Pain201620346547126206340
   PubMed Web of Science ®Google Scholar
• PascualDGoicoecheaCSuardiazMMartinMIA cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in ratsPain20051181–2233416213089
   PubMed Web of Science ®Google Scholar
• BurgosEGomez-NicolaDPascualDMartinMINieto-SampedroMGoicoecheaCCannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cellsEur J Pharmacol20126821–3627222374260
   PubMed Web of Science ®Google Scholar
• VeraGChiarloneACabezosPAPascualDMartinMIAbaloRWIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the ratLife Sci200781646847917673260
   PubMed Web of Science ®Google Scholar
• RahnEJDengLThakurGAProphylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug deliveryMol Pain2014102724742127
   PubMed Web of Science ®Google Scholar
• DengLGuindonJCornettBLMakriyannisAMackieKHohmannAGChronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawalBiol Psychiatry201577547548724853387
   PubMed Web of Science ®Google Scholar
• HarrisHMSufkaKJGulWElSohlyMAEffects of delta-9-tetra-hydrocannabinol and cannabidiol on cisplatin-induced neuropathy in micePlanta Med201682131169117227214593
   PubMed Web of Science ®Google Scholar
• WardSJRamirezMDNeelakantanHWalkerEACannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 miceAnesth Analg2011113494795021737705
   PubMed Web of Science ®Google Scholar
• SegatGCManjavachiMNMatiasDOAntiallodynic effect of beta-caryophyllene on paclitaxel-induced peripheral neuropathy in miceNeuropharmacology201712520721928729222
   PubMed Web of Science ®Google Scholar
• UlugolAKaradagHCIpciYTamerMDokmeciIThe effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic ratsNeurosci Lett20043712–316717015519750
   PubMed Web of Science ®Google Scholar
• VeraGCabezosPAMartinMIAbaloRCharacterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathyPharmacol Biochem Behav201310520521223454533
   PubMed Web of Science ®Google Scholar
• IkedaHIkegamiMKaiMOhsawaMKameiJActivation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic miceNeuroscience201325044645423892011
   PubMed Web of Science ®Google Scholar
• TothCCJedrzejewskiNMEllisCLFreyWHCannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic painMol Pain201061620236533
   PubMed Web of Science ®Google Scholar
• JahanabadiSHadianMRShamsaeeJThe effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic ratsIran J Basic Med Sci201619439440127279983
   PubMed Web of Science ®Google Scholar
• SchreiberAKNeufeldMJesusCHCunhaJMPeripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic ratsNeuropharmacology20126381286129722959964
   PubMed Web of Science ®Google Scholar
• MunawarNOriowoMAMasochaWAntihyperalgesic activities of endocannabinoids in a mouse model of antiretroviral-induced neuropathic painFront Pharmacol2017813628373843
   PubMed Web of Science ®Google Scholar
• HamaASagenJActivation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury painBrain Res20111412445421813113
   PubMed Web of Science ®Google Scholar
• AhmedMMRajpalSSweeneyCCannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury painSpine J201010121049105420920894
   PubMed Web of Science ®Google Scholar
• HamaATUrbanMOAntihyperalgesic effect of the cannabinoid agonist WIN55,212-2 is mediated through an interaction with spinal metabotropic glutamate-5 receptors in ratsNeurosci Lett20043581212415016425
   PubMed Web of Science ®Google Scholar
• WardSJMcAllisterSDKawamuraRMuraseRNeelakantanHWalkerEACannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacyBr J Pharmacol2014171363664524117398
   PubMed Web of Science ®Google Scholar
• RomeroTRResendeLCGuzzoLSDuarteIDCB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic systemAnesth Analg2013116246347223302980
   PubMed Web of Science ®Google Scholar
• SchombergDAhmedMMiranpuriGOlsonJResnickDKNeuropathic pain: role of inflammation, immune response, and ion channel activity in central injury mechanismsAnn Neurosci201219312513225205985
   PubMedGoogle Scholar
• ComelliFBettoniIColomboAFumagalliPGiagnoniGCostaBRimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic miceEur J Pharmacol20106371–3626920399204
   PubMed Web of Science ®Google Scholar
• LiuWJJinHYParkJHBaekHSParkTSEffect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic ratEur J Pharmacol20106371–3707620406631
   PubMed Web of Science ®Google Scholar
• Adamson BarnesNSMitchellVAKazantzisNPVaughanCWActions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain modelBr J Pharmacol20161731778726398331
   PubMed Web of Science ®Google Scholar
• AndersonWBGouldMJTorresRDMitchellVAVaughanCWActions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain modelNeuropharmacology20148122423024384256
   PubMed Web of Science ®Google Scholar
• CostaBSiniscalcoDTrovatoAEAM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic painBr J Pharmacol200614871022103216770320
   PubMed Web of Science ®Google Scholar
• MitchellVAGreenwoodRJayamanneAVaughanCWActions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain modelsClin Exp Pharmacol Physiol200734111186119017880375
   PubMed Web of Science ®Google Scholar
• La RanaGRussoRCampolongoPModulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]J Pharmacol Exp Ther200631731365137116510698
   PubMed Web of Science ®Google Scholar
• JhaveriMDRichardsonDKendallDABarrettDAChapmanVAnalgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic painJ Neurosci20062651133181332717182782
   PubMed Web of Science ®Google Scholar
• RussoRLovermeJLa RanaGThe fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in miceJ Pharmacol Exp Ther2007322123624217412883
   PubMed Web of Science ®Google Scholar
• MaioneSDe PetrocellisLde NovellisVAnalgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptorsBr J Pharmacol2007150676678117279090
   PubMed Web of Science ®Google Scholar
• ClapperJRMoreno-SanzGRussoRAnandamide suppresses pain initiation through a peripheral endocannabinoid mechanismNat Neurosci201013101265127020852626
   PubMed Web of Science ®Google Scholar
• KinseySGLongJZCravattBFLichtmanAHFatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanismsJ Pain201011121420142820554481
   PubMed Web of Science ®Google Scholar
• GhoshSKinseySGLiuQSFull fatty acid amide hydrolase inhibition combined with partial monoacylglycerol lipase inhibition: augmented and sustained antinociceptive effects with reduced cannabimimetic side effects in miceJ Pharmacol Exp Ther2015354211112025998048
   PubMed Web of Science ®Google Scholar
• GuindonJLaiYTakacsSMBradshawHBHohmannAGAlterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatmentPharmacol Res20136719410923127915
   PubMed Web of Science ®Google Scholar
• HugginsJPSmartTSLangmanSTaylorLYoungTAn efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the kneePain201215391837184622727500
   PubMed Web of Science ®Google Scholar
• MückeMPTRadbruchLPetzkeFHäuserWCannabinoids for chronic neuropathic painCochrane Database Syst Rev20165CD012182
   Web of Science ®Google Scholar
• PertweeRGEmerging strategies for exploiting cannabinoid receptor agonists as medicinesBr J Pharmacol2009156339741119226257
   PubMed Web of Science ®Google Scholar
• NotcuttWLangfordRDaviesPRatcliffeSPottsRA placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols)Mult Scler201218221922821878454
   PubMed Web of Science ®Google Scholar
• JohnsonJRLossignolDBurnell-NugentMFallonMTAn open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesicsJ Pain Symptom Manage201346220721823141881
   PubMed Web of Science ®Google Scholar
• DengLGuindonJVemuriVKThe maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB(2) receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathyMol Pain201287122998838
   PubMed Web of Science ®Google Scholar
• UhelskiMLKhasabovaIASimoneDAInhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathyJ Neurophysiol201511351501151025505113
   PubMed Web of Science ®Google Scholar
• KhasabovaIAYaoXPazJJZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathyPharmacol Res201490677525304184
   PubMed Web of Science ®Google Scholar
• Cengelli UnelCAydinSDonertasBEffects of chronic agma-tine administration on cisplatin induced neuropathy in ratsAnatomy201711suppl 1S1S86
   Google Scholar
• DonertasBAydinSCengelli UnelCEffects of chronic anandamide administration on cisplatin induced neuropathy in ratsAnatomy201711suppl 1S1S86
   Google Scholar
• KaygisizBDBAydinSCengelliCYildirimEUlupinarEErolKEffects of anandamide on cisplatin-induced neuropathy and neurotoxicity7th European Congress of Pharmacology, Congress Book P10826–30 İstanbul;2016385
   Google Scholar
• KosselAÜber das agmatinZeitschrift für Physiologische Chemie191166257261
   Google Scholar
• OtakeKRuggieroDARegunathanSWangHMilnerTAReisDJRegional localization of agmatine in the rat brain: an immunocytochemical studyBrain Res199878711149518530
   PubMed Web of Science ®Google Scholar
• LiGRegunathanSBarrowCJEshraghiJCooperRReisDJAgmatine: an endogenous clonidine-displacing substance in the brainScience199426351499669697906055
   PubMed Web of Science ®Google Scholar
• GaleaERegunathanSEliopoulosVFeinsteinDLReisDJInhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginineBiochem J1996316pt 12472498645212
   PubMed Web of Science ®Google Scholar
• ReisDJRegunathanSAgmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitterAnn N Y Acad Sci1999881658010415899
   PubMed Web of Science ®Google Scholar
• DemadyDRJianmongkolSVuletichJLBenderATOsawaYAgmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzymeMol Pharmacol2001591242911125020
   PubMed Web of Science ®Google Scholar
• RaaschWSchäferUChunJDominiakPBiological significance of agmatine, an endogenous ligand at imidazoline binding sitesBr J Pharmacol2001133675578011454649
   PubMed Web of Science ®Google Scholar
• McKayBELadoWEMartinLJGalicMAFournierNMLearning and memory in agmatine-treated ratsPharmacol Biochem Behav200272355155712175451
   PubMed Web of Science ®Google Scholar
• LavinskyDArteniNSNettoCAAgmatine induces anxiolysis in the elevated plus maze task in adult ratsBehav Brain Res20031411192412672555
   PubMed Web of Science ®Google Scholar
• ZhuMYWangWPBissetteGNeuroprotective effects of agmatine against cell damage caused by glucocorticoids in cultured rat hippocampal neuronsNeuroscience200614142019202716777341
   PubMed Web of Science ®Google Scholar
• WuNSuRBLiJAgmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependenceCell Mol Neurobiol200828562964117653850
   PubMed Web of Science ®Google Scholar
• KolesnikovYJainSPasternakGWModulation of opioid analgesia by agmatineEur J Pharmacol1996296117228720472
   PubMed Web of Science ®Google Scholar
• YesilyurtOUzbayITAgmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in miceNeuropsychopharmacology20012519810311377923
   PubMed Web of Science ®Google Scholar
• OnalASoykanNAgmatine produces antinociception in tonic pain in micePharmacol Biochem Behav2001691–2939711420073
   PubMed Web of Science ®Google Scholar
• FairbanksCASchreiberKLBrewerKLAgmatine reverses pain induced by inflammation, neuropathy, and spinal cord injuryProc Natl Acad Sci U S A20009719105841058910984543
   PubMed Web of Science ®Google Scholar
• KaradagHCUlugolATamerMIpciYDokmeciISystemic agmatine attenuates tactile allodynia in two experimental neuropathic pain models in ratsNeurosci Lett20033391889012618307
   PubMed Web of Science ®Google Scholar
• OnalADelenYUlkerSSoykanNAgmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellumLife Sci200373441342812759136
   PubMed Web of Science ®Google Scholar
• RondonLJFargesMCDavinNL-Arginine supplementation prevents allodynia and hyperalgesia in painful diabetic neuropathic rats by normalizing plasma nitric oxide concentration and increasing plasma agmatine concentrationEur J Nutr Epub2017719
   Web of Science ®Google Scholar
• CourteixCPrivatAMPelissierTHernandezAEschalierAFialipJAgmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1-phosphonic acid, a N-methyl-D-aspartate-receptor antagonistJ Pharmacol Exp Ther200732231237124517551093
   PubMed Web of Science ®Google Scholar
• StavniichukRShevalyeHLupachykSPeroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathyDiabetes Metab Res Rev201430866967824687457
   PubMed Web of Science ®Google Scholar
• KasznickiJKosmalskiMSliwinskaAEvaluation of oxidative stress markers in pathogenesis of diabetic neuropathyMol Biol Rep20123998669867822718504
   PubMed Web of Science ®Google Scholar
• PieperGMDondlingerLAPlasma and vascular tissue arginine are decreased in diabetes: acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP productionJ Pharmacol Exp Ther199728326846919353386
   PubMed Web of Science ®Google Scholar
• HaghighiSSJohnsonGCde VergelCFVergel RivasBJPretreatment with NMDA receptor antagonist MK801 improves neurophysiological outcome after an acute spinal cord injuryNeurol Res19961865095158985951
   PubMed Web of Science ®Google Scholar
• GrossmanSDWolfeBBYasudaRPWrathallJRAlterations in AMPA receptor subunit expression after experimental spinal cord contusion injuryJ Neurosci199919145711572010407012
   PubMed Web of Science ®Google Scholar
• HamadaYIkataTKatohSRoles of nitric oxide in compression injury of rat spinal cordFree Radic Biol Med1996201198903674
   PubMed Web of Science ®Google Scholar
• BrightwellJJTaylorBKNoradrenergic neurons in the locus coeruleus contribute to neuropathic painNeuroscience2009160117418519223010
   PubMed Web of Science ®Google Scholar
• MillanMJDescending control of painProg Neurobiol200266635547412034378
   PubMed Web of Science ®Google Scholar
• BrechtSCourtecuisseCDebieuvreCEfficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trialJ Clin Psychiatry200768111707171618052564
   PubMed Web of Science ®Google Scholar
• PertovaaraANoradrenergic pain modulationProg Neurobiol2006802538317030082
   PubMed Web of Science ®Google Scholar
• JonesSLGebhartGFQuantitative characterization of ceruleospinal inhibition of nociceptive transmission in the ratJ Neurophysiol1986565139714103025380
   PubMed Web of Science ®Google Scholar
• HayashidaKEisenachJCSpinal alpha 2-adrenoceptor-mediated analgesia in neuropathic pain reflects brain-derived nerve growth factor and changes in spinal cholinergic neuronal functionAnesthesiology2010113240641220613480
   PubMed Web of Science ®Google Scholar
• YangXCReisDJAgmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neuronsJ Pharmacol Exp Ther199928825445499918557
   PubMed Web of Science ®Google Scholar
• DonertasBCengelli UnelCAydinSAgmatine co-treatment attenuates allodynia and structural abnormalities in cisplatin-induced neuropathy in ratsFundam Clin Pharmacol Epub2018 129
   Web of Science ®Google Scholar
• SmithJCWhittonPSNitric oxide modulates N-methyl-D-aspartate-evoked serotonin release in the raphe nuclei and frontal cortex of the freely moving ratNeurosci Lett200029115810962140
   PubMed Web of Science ®Google Scholar
• KigerlKAGenselJCAnkenyDPAlexanderJKDonnellyDJPopovichPGIdentification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cordJ Neurosci20092943134351344419864556
   PubMed Web of Science ®Google Scholar
• KimJHKimJYMunCHSuhMLeeJEAgmatine modulates the phenotype of macrophage acute phase after spinal cord injury in ratsExp Neurobiol201726527828629093636
   PubMed Web of Science ®Google Scholar
• MaSFChenYJZhangJXAdoptive transfer of M2 macrophages promotes locomotor recovery in adult rats after spinal cord injuryBrain Behav Immun20154515717025476600
   PubMed Web of Science ®Google Scholar
• PalaciosGMuroAVerduEPumarolaMVelaJMImmunohistochemical localization of the sigma1 receptor in Schwann cells of rat sciatic nerveBrain Res200410071–2657015064136
   PubMed Web of Science ®Google Scholar
• de la PuenteBNadalXPortillo-SalidoESigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injuryPain2009145329430319505761
   PubMed Web of Science ®Google Scholar
• MartuscelloRTSpenglerRNBonoiuACIncreasing TNF levels solely in the rat hippocampus produces persistent pain-like symptomsPain201215391871188222770843
   PubMed Web of Science ®Google Scholar
• KotagaleNRShirbhateSHShuklaPUgaleRRAgmatine attenuates neuropathic pain in sciatic nerve ligated rats: modulation by hippocampal sigma receptorsEur J Pharmacol20137141–342443123872381
   PubMed Web of Science ®Google Scholar
• SantosARGadottiVMOliveiraGLMechanisms involved in the antinociception caused by agmatine in miceNeuropharmacology20054871021103415857629
   PubMed Web of Science ®Google Scholar
• RegunathanSAgmatine: biological role and therapeutic potentials in morphine analgesia and dependenceAAPS J200683E479E48417025265
   PubMed Web of Science ®Google Scholar